Answers are grounded in this paper and cite their sources.
In vitro study reveals hyaluronic acid molecular weight does not alter platelet-rich plasma cytokine release in healthy males, suggesting both formulations offer comparable biological activity.
Aims Platelet-rich plasma (PRP) and hyaluronic acid (HA) are nonoperative treatments for osteoarthritis (OA) of large joints. Clinically, some endorse the use of both methods together for a theoretical synergistic effect therapeutically, with limited evidence. This study aimed to evaluate whether the molecular weight of HA influences the cytokines released from PRP in vitro. Methods Leucocyte-rich PRP was prepared from venous blood of ten healthy males (aged 18 to 35 years). Three groups were tested: PRP + phosphate-buffered saline (PBS, control), PRP + low molecular weight HA (LMWHA, and PRP + high molecular weight HA (HMWHA). Samples were incubated at 37°C, and the concentrations of insulin-like growth factor binding protein 1 (IGFBP1), interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-10, platelet-derived growth factor subunit B (PDGF-BB), transforming growth factor-β (TGF-β1), and tumour necrosis factor-alpha (TNF-α) were measured at two hours (Day 0) and 72 hours (Day 3). Data were analyzed using repeated measures analysis of variance (p < 0.05). A Bonferroni test was performed as a post hoc analysis. Results PDGF-BB decreased significantly (p < 0.001) from Day 0 to 3 across all groups. This was more pronounced in the presence of HA, regardless of molecular weight. IL-1β rose significantly in HA-treated groups only (p = 0.009). No significant intergroup differences emerged for IGFBP1, IL-6, TGF-β1, or TNF-α at either timepoint. There was a significant increase in both IL-1RA (p = 0.016), and IL-10 (p < 0.001) concentration from Day 0 to 3. There were no significant differences in IL-1RA or IL-10 between the control, LMWHA, and HMWHA groups at Day 0 or 3. Conclusion The molecular weight of HA did not improve the cytokine profile of PRP in vitro, suggesting that both LMWHA and HMWHA formulations may be comparable when used in combination with PRP, at least in males. Cite this article: Bone Joint Res 2026;15(8):1067–1073.
No takes yet. Share an insight, caveat, or question.
Ellenbogen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: